Related Experiment Videos
Myeloma bone disease
1Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, TX, USA.
Abstract:
Bone destruction is a hallmark of myeloma, with 70% to 80% of patients manifesting bone involvement. Destruction is mediated through normal osteoclasts (OCLs), which respond to local osteoclast-activating factors (OAFs) produced by myeloma cells or by other cells in the local microenvironment. OAFs implicated in myeloma bone disease include tumor necrosis factor-beta (TNFbeta), RANK ligand (RANKL), interleukin-1 (IL-1), parathyroid hormone-related protein (PTHrP), hepatocyte growth factor (HGH), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFalpha), and macrophage inflammatory protein-1-alpha (MIP-1alpha). To date, the leading candidates for OAFs are MIP-1alpha and RANKL. Adhesive interactions between marrow stromal cells and myeloma cells induce marrow stromal cells to secrete IL-6, a potent myeloma growth/survival factor that may contribute to the bone disease. Evaluation of myeloma bone disease includes plain radiographs, and newer methods, such as magnetic resonance imaging (MRI), positron emission tomography (PET) scans, technetium-99m-sestamibi (Mibi) scanning, and dual-energy x-ray absorptiometry (DEXA) scanning, may provide more complete information. In addition, biochemical markers of bone resorption are being evaluated, although the limited availability of these assays and lack of extensive testing in patients make their routine use premature. Treatment of myeloma bone disease includes radiation therapy, vertebroplasty, surgery, and bisphosphonates. New developments on the pathogenesis and treatment of myeloma bone disease present great opportunities to combat bone disease.
Insights
Myeloma bone disease involves significant bone destruction due to osteoclast-activating factors (OAFs). Understanding these factors and utilizing advanced imaging and treatments offers new hope for managing myeloma bone complications.
Area of Science:
- Oncology
- Bone Biology
- Biochemistry
Background:
- Bone destruction is a common and severe complication in multiple myeloma, affecting 70-80% of patients.
- Myeloma bone disease is driven by osteoclast-activating factors (OAFs) produced by myeloma cells and the microenvironment.
Purpose of the Study:
- To review the key osteoclast-activating factors (OAFs) involved in myeloma bone disease.
- To discuss current and emerging diagnostic methods for evaluating myeloma bone disease.
- To outline existing and potential therapeutic strategies for managing myeloma bone complications.
Main Methods:
- Review of literature on myeloma bone disease pathogenesis, diagnosis, and treatment.
- Identification of key osteoclast-activating factors (OAFs) such as macrophage inflammatory protein-1-alpha (MIP-1alpha) and RANK ligand (RANKL).
- Summary of diagnostic imaging modalities including radiography, MRI, PET, Mibi, and DEXA scanning.
Main Results:
- Multiple OAFs contribute to myeloma bone disease, with MIP-1alpha and RANKL being leading candidates.
- IL-6, secreted by marrow stromal cells, promotes myeloma growth and may contribute to bone disease.
- Advanced imaging techniques provide more comprehensive evaluation of bone involvement compared to plain radiographs.
Conclusions:
- Understanding the pathogenesis of myeloma bone disease, including the role of OAFs, is crucial for developing effective treatments.
- Multimodal diagnostic approaches enhance the assessment of bone involvement in myeloma patients.
- Ongoing research into the pathogenesis and treatment of myeloma bone disease offers promising avenues for patient care.